Information Provided By: 
Fly News Breaks for September 6, 2018
SPPI
Sep 6, 2018 | 09:19 EDT
Jefferies analyst Matthew Andrews says the new interim poziotinib data from the MD Anderson Phase 2 non-small cell lung cancer study "don't disappoint." Shares of Spectrum Pharmaceuticals should begin to retrace the drop since last week amid concerns about the Korean poziotinib HER2 data, Andrews tells investors in a research note. The analyst believes the unconfirmed overall response rate of 58% in EGFR and 50% in HER2 are "impressive." He keeps a Buy rating on Spectrum with a $25 price target.
News For SPPI From the Last 2 Days
There are no results for your query SPPI
